China's Waterstone Pharma In-licenses Hepatitis C Drug from SCYNEXIS

Waterstone Pharmaceutical of Wuhan, China obtained global rights to a treatment for chronic viral infections from SCYNEXIS, a North Carolina anti-infectives company. The drug, SCY-635, has completed a Phase II trial in patients with hepatitis C. Waterstone, which describes itself as an international company with its main operations in China, develops novel drugs for liver and gastrointestinal diseases. The company is backed by well-known investors including BAR Capital, CID Group, OrbiMed and Acorn Camps. More details....